Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 25, Issue 1, 2006, Pages 25-30

  Balke, B ^a   Hogardt, M ^b   Schmoldt, S ^b   Hoy, L ^a   Weissbrodt, H ^a   Haussler S ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIBIOTIC AGENT; CEFTAZIDIME; MEROPENEM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DILUTION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; E TEST; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS AERUGINOSA; STATISTICAL ANALYSIS;

EID: 32144446281     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-0076-9     Document Type: Article

References (31)

1. Gilligan PH (1991) Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4:35-51
2. Lyczak JB, Cannon CL, Pier GB (2002) Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194-222
3. Tummler B, Kiewitz C (1999) Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections. Mol Med Today 5:351-358
4. Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918-951
5. FitzSimmons SC (1993) The changing epidemiology of cystic fibrosis. J Pediatr 122:1-9
6. Ramsey BW (1996) Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335:179-188
7. Mouton JW, Den Hollander JG, Horrevorts AM (1993) Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 31:919-926
8. Chernish RN, Aaron SD (2003) Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med 9:509-515
9. Hancock RE, Raffle VJ, Nicas TI (1981) Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 19:777-785
10. Miller MH, Feinstein SA, Chow RT (1987) Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa. Antimicrob Agents Chemother 31:108-110
11. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC (1990) Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 141:914-921
12. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R (1999) Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 134:413-421
13. Baltch AL, Bassey C, Hammer MC, Smith RP, Conroy JV, Michelsen PB (1991) Synergy with cefsulodin or piperacillin and three aminoglycosides or aztreonam against aminoglycoside-resistant strains of Pseudomonas aeruginosa. J Antimicrob Chemother 27:801-808
14. Cappelletty DM, Rybak MJ (1996) Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 40:677-683
15. Chin NX, Neu HC (1989) Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia. Diagn Microbiol Infect Dis 12:343-349
16. Den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW (1997) Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 41:95-100
17. Heineman HS, Lofton WM (1978) Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitro. Antimicrob Agents Chemother 13:827-831
18. Meyer RD, Liu S (1988) In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 11:151-157
19. Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, Marshall SA, Jones RN (2000) Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 38:1818-1822
20. Di Bonaventura G, Ricci E, Della LN, Catamo G, Piccolomini R (1998) Evaluation of the E test for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from patients with long-term bladder catheterization. J Clin Microbiol 36:824-826
21. Joyce LF, Downes J, Stockman K, Andrew HJ (1992) Comparison of five methods, including the PDM Epsilometer test (E test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa. J Clin Microbiol 30:2709-2713
22. Marley EF, Mohla C, Campos JM (1995) Evaluation of E-test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 33:3191-3193
23. Bonapace CR, White RL, Friedrich LV, Bosso JA (2000) Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with E test, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 38:43-50
24. Manno G, Ugolotti E, Belli ML, Fenu ML, Romano L, Cruciani M (2003) Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 22:28-34
25. White RL, Burgess DS, Manduru M, Bosso JA (1996) Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40:1914-1918
26. Balke B, Hoy L, Weissbrodt H, Haussler S (2004) Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 23:765-771
27. National Committee of Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S12. NCCLS, Wayne, PA,
28. Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE (2000) Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 162:2241-2245
29. Rautelin H, Renkonen L, Renkonen OV (1992) Evaluation of the E test in testing susceptibility of Pseudomonas aeruginosa to tobramycin. Eur J Clin Microbiol Infect Dis 11:177-180
30. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A (1996) Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 23:532-537
31. Weiss K, Lapointe RJ (1995) Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother 39:2411-2414